Class Action Lawsuit Filed on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors – Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Marinus Pharmaceuticals, alleging that the company made materially false and misleading statements regarding its business and operations [3] - The lawsuit specifically claims that Marinus understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose the potential consequences of such failure, including the possibility of stopping the Phase 3 RAISE II trial [3] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is August 5, 2024 [4] Company Information - Marinus Pharmaceuticals, Inc. is publicly traded on NASDAQ under the ticker MRNS [3] - The company is currently facing legal challenges related to its disclosures and operational risks, which may impact investor confidence and stock performance [3] Legal Representation - Holzer & Holzer, LLC is representing shareholders in this litigation, emphasizing their commitment to recovering losses for investors affected by corporate misconduct [2] - The firm has a history of recovering hundreds of millions of dollars for shareholders since its founding in 2000 [2]